The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Association of increased tumor-infiltrating lymphocytes (TILs) with immunomodulatory (IM) triple-negative breast cancer (TNBC) subtype and response to neoadjuvant platinum-based therapy in PrECOG0105.
Shaveta Vinayak
No relevant relationships to disclose
Robert James Gray
No relevant relationships to disclose
Sylvia Adams
No relevant relationships to disclose
Kristin C. Jensen
No relevant relationships to disclose
Judith Manola
Research Funding - Sanofi
Anosheh Afghahi
No relevant relationships to disclose
Lori J. Goldstein
No relevant relationships to disclose
James M. Ford
Research Funding - Myriad Genetics; Sanofi
Sunil S. Badve
No relevant relationships to disclose
Melinda L. Telli
Consultant or Advisory Role - Myriad Genetics (U); Sanofi (U)
Research Funding - Sanofi